Fundraising
We are inviting you to become a first round partner and sponsor in the AGILE Coronavirus Drug Testing Initiative.
Other posts
AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2
The antiviral drug molnupiravir received regulatory approval for treating people with mild to moderate COVID-19…
Learning and confirming in publicly funded antiviral trials
Reporting the phase 2 results from the UK AGILE CST-2 study of molnupiravir for SARS-CoV-2…
First antiviral pill to treat Covid-19 approved in UK
A “game-changing” antiviral pill that is part of the AGILE Coronavirus Drug Testing Initiative has…
AGILE Covid-19 drug testing platform opens new trial in South Africa
A new international trial to assess whether high doses of the antiparasitic drug nitazoxanide could…
First patient dosed in latest stage of AGILE COVID-19 drug trial
LIVERPOOL, England, 20 April 2021 — The University of Liverpool, Liverpool School of Tropical Medicine,…
People across the south to be part of pioneering research in the fight against COVID-19
People across the south are being asked to play their part in helping vital research…